Comparison of Effects of Morning Versus Evening Administration of Ezetimibe/Simvastatin on Serum Cholesterol in Patients with Primary Hypercholesterolemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Hyung Sik | - |
dc.contributor.author | Kim, Sung Ho | - |
dc.contributor.author | Kim, Jeong Kyung | - |
dc.contributor.author | Ko, Sang Hun | - |
dc.contributor.author | Ko, Jae Ee | - |
dc.contributor.author | Park, Soo Jin | - |
dc.contributor.author | Park, Moon Gi | - |
dc.contributor.author | Lee, Jae Hwan | - |
dc.contributor.author | Hyon, Min Soo | - |
dc.date.accessioned | 2021-08-12T05:26:18Z | - |
dc.date.available | 2021-08-12T05:26:18Z | - |
dc.date.issued | 2011-07 | - |
dc.identifier.issn | 1060-0280 | - |
dc.identifier.issn | 1542-6270 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/16384 | - |
dc.description.abstract | BACKGROUND: Ezetimibe, a first-in-its-class inhibitor of cholesterol absorption, is an effective agent for combined use with statins to achieve low-density lipoprotein cholesterol (LDL-C) goals. Ezetimibe in combination with simvastatin as a single-tablet formulation has proven to be highly effective in reducing serum LDL-C through the dual inhibition of cholesterol absorption and biosynthesis. The effect of time of administration on efficacy of this combination therapy has not been evaluated. OBJECTIVE: To compare the effects of morning versus evening administration of ezetimibe/simvastatin on serum cholesterol levels of patients with primary hypercholesterolemia. METHODS: In this multicenter, open-label, randomized, 2-sequence, 2-period crossover study, patients with primary hypercholesterolemia randomly received ezetimibe/simvastatin 10 mg/20 mg once daily, either in the morning (within 1 hour of breakfast) or in the evening (within 1 hour of dinner) for 6 weeks. RESULTS: Data on 171 patients (87 in the morning administration group and 84 in the evening administration group) were analyzed. A significant reduction (p <= 0.001) in the total cholesterol, triglyceride, high-density lipoprotein cholesterol, LDL-C, apo-lipoprotein B, and high-sensitivity C-reactive protein (hs-CRP) from baseline was achieved after each treatment. Noninferiority of morning administration versus evening administration was shown in the percentage reduction of the LDL-C level from baseline (difference, -1.62%; 90% CI -4.94 to 1.70). No significant difference was found between groups with respect to the percentage of changes in other lipid parameters from baseline. Furthermore, there was no significant difference in the percentage of change in hs-CRP as an antiinflammatory marker between the morning and evening administration groups. The frequency of adverse events was similar between groups. CONCLUSIONS: Morning administration of ezetimibe/simvastatin 10 mg/20 mg is noninferior to evening administration with respect to LDL-C-lowering ability. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Harvey Whitney Books Company | - |
dc.title | Comparison of Effects of Morning Versus Evening Administration of Ezetimibe/Simvastatin on Serum Cholesterol in Patients with Primary Hypercholesterolemia | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1345/aph.1P511 | - |
dc.identifier.scopusid | 2-s2.0-79960752475 | - |
dc.identifier.wosid | 000293370300001 | - |
dc.identifier.bibliographicCitation | Annals of Pharmacotherapy, v.45, no.7-8, pp 841 - 849 | - |
dc.citation.title | Annals of Pharmacotherapy | - |
dc.citation.volume | 45 | - |
dc.citation.number | 7-8 | - |
dc.citation.startPage | 841 | - |
dc.citation.endPage | 849 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | C-REACTIVE PROTEIN | - |
dc.subject.keywordPlus | CORONARY-HEART-DISEASE | - |
dc.subject.keywordPlus | MIDDLE-AGED MEN | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | STATIN THERAPY | - |
dc.subject.keywordPlus | EZETIMIBE | - |
dc.subject.keywordPlus | SIMVASTATIN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordAuthor | chronobiologic variation | - |
dc.subject.keywordAuthor | ezetimibe | - |
dc.subject.keywordAuthor | high-sensitivity C-reactive protein | - |
dc.subject.keywordAuthor | hypercholesterolemia | - |
dc.subject.keywordAuthor | simvastatin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.